Advanced Expertise inComplex Red Cell Disorders

Versiti’s donor red cell genotyping supports development of a well-characterized donor pool to meet current and future transfusion needs. High-throughput molecular screening identifies common, uncommon, and rare antigens, including those relevant to patients with sickle cell disease and thalassemia. 

Compared with serologic typing, molecular donor screening improves efficiency, reduces repeat testing, and strengthens availability of antigen-matched red blood cell units. 

Donor genotyping supports: 

• Efficient identification of antigen-negative units
• Reduced serologic screening burden
• Improved readiness for complex transfusion needs

Versiti’s patient red cell genotyping panels provide accurate antigen profiles when serologic testing is unreliable. Molecular testing characterizes clinically significant blood group alleles before or during treatment, supporting informed transfusion planning. 

These panels are particularly useful for patients with warm autoantibodies, positive DATs, or recent transfusion history. 

Patient genotyping panels offer: 

• Coverage of clinically significant antigens
• Turnaround times typically under72 hours
• Consistent, clinically validated results

Versiti has provided prenatal red cell genotyping since 1995, supporting evaluation and management of hemolytic disease of the fetus and newborn. 

Physicians collaborate directly with clinical teams on high-risk pregnancies, including transfusion planning and intrauterine transfusions. 

Prenatal genotyping services include: 

• Targeted single-antigen testing
• Case-based maternal, paternal, and fetal evaluation
• Access to antigen-negative and CMV-negative red blood cell units for intrauterine transfusion